Publisher Correction: ERK1/2 phosphorylation predicts survival following anti-PD-1 immunotherapy in recurrent glioblastoma (Nature Cancer, (2021), 2, 12, (1372-1386), 10.1038/s43018-021-00260-2)

Víctor A. Arrieta; Andrew X. Chen; J. Robert Kane; Seong Jae Kang; Cynthia Kassab; Crismita Dmello; Junfei Zhao; Kirsten B. Burdett; Pavan S. Upadhyayula; Catalina Lee-Chang; Joseph Shilati; Dinesh Jaishankar; Li Chen; Andrew Gould; Daniel Zhang; Jinzhou Yuan; Wenting Zhao; Xiaoyang Ling; Jared K. Burks; Brice Laffleur; Christina Amidei; Jeffrey N. Bruce; Rimas V. Lukas; Jonathan T. Yamaguchi; David Cieremans; Gerson Rothschild; Uttiya Basu; Matthew McCord; Daniel J. Brat; Hui Zhang; Lee A.D. Cooper; Bin Zhang; Peter Sims; Tim F. Cloughesy; Robert Prins; Peter Canoll; Roger Stupp; Amy B. Heimberger; Craig Horbinski; Fabio M. Iwamoto; Raul Rabadan; Adam M. Sonabend

doi:10.1038/s43018-022-00343-8

Publisher Correction: ERK1/2 phosphorylation predicts survival following anti-PD-1 immunotherapy in recurrent glioblastoma (Nature Cancer, (2021), 2, 12, (1372-1386), 10.1038/s43018-021-00260-2)

Víctor A. Arrieta, Andrew X. Chen, J. Robert Kane, Seong Jae Kang, Cynthia Kassab, Crismita Dmello, Junfei Zhao, Kirsten B. Burdett, Pavan S. Upadhyayula, Catalina Lee-Chang, Joseph Shilati, Dinesh Jaishankar, Li Chen, Andrew Gould, Daniel Zhang, Jinzhou Yuan, Wenting Zhao, Xiaoyang Ling, Jared K. Burks, Brice LaffleurChristina Amidei, Jeffrey N. Bruce, Rimas V. Lukas, Jonathan T. Yamaguchi, David Cieremans, Gerson Rothschild, Uttiya Basu, Matthew McCord, Daniel J. Brat, Hui Zhang, Lee A.D. Cooper, Bin Zhang, Peter Sims, Tim F. Cloughesy, Robert Prins, Peter Canoll, Roger Stupp, Amy B. Heimberger, Craig Horbinski, Fabio M. Iwamoto^*, Raul Rabadan^*, Adam M. Sonabend^*

^*Corresponding author for this work

Research output: Contribution to journal › Comment/debate › peer-review

Abstract

In the version of this article initially published, there was an error in the author affiliations for Gerson Rothschild and Uttiya Basu. Both authors are affiliated with the Department of Microbiology and Immunology, Columbia University, New York, NY, USA, and not, as originally published, University of Rennes 1. The affiliations have been updated in the HTML and PDF versions of the article.

Original language	English (US)
Pages (from-to)	373
Number of pages	1
Journal	Nature Cancer
Volume	3
Issue number	3
DOIs	https://doi.org/10.1038/s43018-022-00343-8
State	Published - Mar 2022

ASJC Scopus subject areas

Oncology
Cancer Research

UN SDGs

This output contributes to the following UN Sustainable Development Goals (SDGs)

Access to Document

10.1038/s43018-022-00343-8

Cite this

Arrieta, V. A., Chen, A. X., Kane, J. R., Kang, S. J., Kassab, C., Dmello, C., Zhao, J., Burdett, K. B., Upadhyayula, P. S., Lee-Chang, C., Shilati, J., Jaishankar, D., Chen, L., Gould, A., Zhang, D., Yuan, J., Zhao, W., Ling, X., Burks, J. K., ... Sonabend, A. M. (2022). Publisher Correction: ERK1/2 phosphorylation predicts survival following anti-PD-1 immunotherapy in recurrent glioblastoma (Nature Cancer, (2021), 2, 12, (1372-1386), 10.1038/s43018-021-00260-2). Nature Cancer, 3(3), 373. https://doi.org/10.1038/s43018-022-00343-8

@article{cd32f8bc52fb4ae385941554158a0bbc,

title = "Publisher Correction: ERK1/2 phosphorylation predicts survival following anti-PD-1 immunotherapy in recurrent glioblastoma (Nature Cancer, (2021), 2, 12, (1372-1386), 10.1038/s43018-021-00260-2)",

abstract = "In the version of this article initially published, there was an error in the author affiliations for Gerson Rothschild and Uttiya Basu. Both authors are affiliated with the Department of Microbiology and Immunology, Columbia University, New York, NY, USA, and not, as originally published, University of Rennes 1. The affiliations have been updated in the HTML and PDF versions of the article.",

author = "Arrieta, {V{\'i}ctor A.} and Chen, {Andrew X.} and Kane, {J. Robert} and Kang, {Seong Jae} and Cynthia Kassab and Crismita Dmello and Junfei Zhao and Burdett, {Kirsten B.} and Upadhyayula, {Pavan S.} and Catalina Lee-Chang and Joseph Shilati and Dinesh Jaishankar and Li Chen and Andrew Gould and Daniel Zhang and Jinzhou Yuan and Wenting Zhao and Xiaoyang Ling and Burks, {Jared K.} and Brice Laffleur and Christina Amidei and Bruce, {Jeffrey N.} and Lukas, {Rimas V.} and Yamaguchi, {Jonathan T.} and David Cieremans and Gerson Rothschild and Uttiya Basu and Matthew McCord and Brat, {Daniel J.} and Hui Zhang and Cooper, {Lee A.D.} and Bin Zhang and Peter Sims and Cloughesy, {Tim F.} and Robert Prins and Peter Canoll and Roger Stupp and Heimberger, {Amy B.} and Craig Horbinski and Iwamoto, {Fabio M.} and Raul Rabadan and Sonabend, {Adam M.}",

note = "Publisher Copyright: {\textcopyright} 2022, The Author(s), under exclusive licence to Springer Nature America, Inc.",

year = "2022",

month = mar,

doi = "10.1038/s43018-022-00343-8",

language = "English (US)",

volume = "3",

pages = "373",

journal = "Nature Cancer",

issn = "2662-1347",

publisher = "Nature Research",

number = "3",

}

Arrieta, VA, Chen, AX, Kane, JR, Kang, SJ, Kassab, C, Dmello, C, Zhao, J, Burdett, KB, Upadhyayula, PS, Lee-Chang, C, Shilati, J, Jaishankar, D, Chen, L, Gould, A, Zhang, D, Yuan, J, Zhao, W, Ling, X, Burks, JK, Laffleur, B, Amidei, C, Bruce, JN, Lukas, RV, Yamaguchi, JT, Cieremans, D, Rothschild, G, Basu, U, McCord, M, Brat, DJ , Zhang, H , Cooper, LAD , Zhang, B, Sims, P, Cloughesy, TF, Prins, R, Canoll, P, Stupp, R , Heimberger, AB , Horbinski, C, Iwamoto, FM, Rabadan, R & Sonabend, AM 2022, 'Publisher Correction: ERK1/2 phosphorylation predicts survival following anti-PD-1 immunotherapy in recurrent glioblastoma (Nature Cancer, (2021), 2, 12, (1372-1386), 10.1038/s43018-021-00260-2)', Nature Cancer, vol. 3, no. 3, pp. 373. https://doi.org/10.1038/s43018-022-00343-8

Publisher Correction: ERK1/2 phosphorylation predicts survival following anti-PD-1 immunotherapy in recurrent glioblastoma (Nature Cancer, (2021), 2, 12, (1372-1386), 10.1038/s43018-021-00260-2). / Arrieta, Víctor A.; Chen, Andrew X.; Kane, J. Robert et al.
In: Nature Cancer, Vol. 3, No. 3, 03.2022, p. 373.

Research output: Contribution to journal › Comment/debate › peer-review

TY - JOUR

T1 - Publisher Correction

T2 - ERK1/2 phosphorylation predicts survival following anti-PD-1 immunotherapy in recurrent glioblastoma (Nature Cancer, (2021), 2, 12, (1372-1386), 10.1038/s43018-021-00260-2)

AU - Arrieta, Víctor A.

AU - Chen, Andrew X.

AU - Kane, J. Robert

AU - Kang, Seong Jae

AU - Kassab, Cynthia

AU - Dmello, Crismita

AU - Zhao, Junfei

AU - Burdett, Kirsten B.

AU - Upadhyayula, Pavan S.

AU - Lee-Chang, Catalina

AU - Shilati, Joseph

AU - Jaishankar, Dinesh

AU - Chen, Li

AU - Gould, Andrew

AU - Zhang, Daniel

AU - Yuan, Jinzhou

AU - Zhao, Wenting

AU - Ling, Xiaoyang

AU - Burks, Jared K.

AU - Laffleur, Brice

AU - Amidei, Christina

AU - Bruce, Jeffrey N.

AU - Lukas, Rimas V.

AU - Yamaguchi, Jonathan T.

AU - Cieremans, David

AU - Rothschild, Gerson

AU - Basu, Uttiya

AU - McCord, Matthew

AU - Brat, Daniel J.

AU - Zhang, Hui

AU - Cooper, Lee A.D.

AU - Zhang, Bin

AU - Sims, Peter

AU - Cloughesy, Tim F.

AU - Prins, Robert

AU - Canoll, Peter

AU - Stupp, Roger

AU - Heimberger, Amy B.

AU - Horbinski, Craig

AU - Iwamoto, Fabio M.

AU - Rabadan, Raul

AU - Sonabend, Adam M.

PY - 2022/3

Y1 - 2022/3

N2 - In the version of this article initially published, there was an error in the author affiliations for Gerson Rothschild and Uttiya Basu. Both authors are affiliated with the Department of Microbiology and Immunology, Columbia University, New York, NY, USA, and not, as originally published, University of Rennes 1. The affiliations have been updated in the HTML and PDF versions of the article.

AB - In the version of this article initially published, there was an error in the author affiliations for Gerson Rothschild and Uttiya Basu. Both authors are affiliated with the Department of Microbiology and Immunology, Columbia University, New York, NY, USA, and not, as originally published, University of Rennes 1. The affiliations have been updated in the HTML and PDF versions of the article.

UR - http://www.scopus.com/inward/record.url?scp=85124545085&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85124545085&partnerID=8YFLogxK

U2 - 10.1038/s43018-022-00343-8

DO - 10.1038/s43018-022-00343-8

M3 - Comment/debate

C2 - 35149861

AN - SCOPUS:85124545085

SN - 2662-1347

VL - 3

SP - 373

JO - Nature Cancer

JF - Nature Cancer

IS - 3

ER -

Publisher Correction: ERK1/2 phosphorylation predicts survival following anti-PD-1 immunotherapy in recurrent glioblastoma (Nature Cancer, (2021), 2, 12, (1372-1386), 10.1038/s43018-021-00260-2)

Abstract

ASJC Scopus subject areas

UN SDGs

Access to Document

Other files and links

Fingerprint

Cite this